AbSci hopes to make E. Coli great again through engineered expression system
AbSci says its genetically engineered E. coli expression platform has produced yields exceeding 20 g/L for difficult to express products and threatens the dominance of mammalian systems …
2017: A Big Year for AbSci – Growth and Continued Expansion
AbSci, a global leader in breakthrough biomanufacturing technologies, today announced that it is further expanding its offices and laboratory facilities. “We’ve seen a significant increase in partnership deal flow, which is a testament to the innovation and quality of work performed by our scientists,” said CEO and Founder, Sean McClain …
AbSci named PBJ’s Small Business Innovation Award Winner for 2017
AbSci to be named one of Portland’s most innovative companies of the year. The awards ceremony will take place at Portland’s Hilton Hotel Wednesday, November 1st. You can read more about the event here.
US Patent Granted for SoluPro™ Technology
Vancouver, WA – April 11, 2017 United States Patent No. 9,617,335 was issued today to AbSci, an industry leader in biomanufacturing innovation, for its SoluPro™ protein expression system, which produces complex therapeutic proteins at unparalleled yield and throughput...
AbSci Receives European Patent on its SoluPro™ Expression Platform
AbSci a global leader in biomanufacturing technologies, was granted a European regional patent today for its SoluPro™ protein production technology. “Many years of discovery went into developing the SoluPro™ expression platform. The SoluPro™ technology provides a revolutionary solution to one of biomanufacturing’s ongoing challenges …